Literature DB >> 25596271

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.

Michael W M Kühn1, Michael J Hadler1, Scott R Daigle2, Richard P Koche1, Andrei V Krivtsov1, Edward J Olhava2, Michael A Caligiuri3, Gang Huang4, James E Bradner5, Roy M Pollock2, Scott A Armstrong6.   

Abstract

Entities:  

Keywords:  DOT1L inhibition; MLL-PTD; leukemia

Mesh：

Substances：

Year:  2015        PMID： 25596271      PMCID： PMC4420229          DOI： 10.3324/haematol.2014.115337

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Molecular characterization of acute myeloid leukemia.

Authors:  Konstanze Döhner; Hartmut Döhner
Journal:  Haematologica       Date:  2008-07       Impact factor: 9.941

2.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 3.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

4.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

5.  DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.

Authors:  Anh Tram Nguyen; Olena Taranova; Jin He; Yi Zhang
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

6.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

Authors:  Konstanze Döhner; Karen Tobis; Regina Ulrich; Stefan Fröhling; Axel Benner; Richard F Schlenk; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.

Authors:  Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

8.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Authors:  Aniruddha J Deshpande; Liying Chen; Maurizio Fazio; Amit U Sinha; Kathrin M Bernt; Deepti Banka; Stuart Dias; Jenny Chang; Edward J Olhava; Scott R Daigle; Victoria M Richon; Roy M Pollock; Scott A Armstrong
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

Review 9.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.

Authors:  Tobias Neff; Scott A Armstrong
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

10.  Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Authors:  Susan P Whitman; Amy S Ruppert; Guido Marcucci; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Tamara Vukosavljevic; Bayard L Powell; Andrew J Carroll; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Clara D Bloomfield
Journal:  Blood       Date:  2007-03-06       Impact factor: 22.113
View more
  28 in total

Review 1.  New drugs for acute myeloid leukemia inspired by genomics and when to use them.

Authors:  Daniel A Pollyea
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Authors:  Henrik Möbitz; Rainer Machauer; Philipp Holzer; Andrea Vaupel; Frédéric Stauffer; Christian Ragot; Giorgio Caravatti; Clemens Scheufler; Cesar Fernandez; Ulrich Hommel; Ralph Tiedt; Kim S Beyer; Chao Chen; Hugh Zhu; Christoph Gaul
Journal:  ACS Med Chem Lett       Date:  2017-02-14       Impact factor: 4.345

3.  Amplification of mixed lineage leukemia gene perturbs hematopoiesis and cooperates with partial tandem duplication to induce acute myeloid leukemia.

Authors:  Bon Ham Yip; Chiou Tsun Tsai; Jayant K Rane; Winston Vetharoy; Eduardo Anguita; Shuo Dong; Michael A Caligiuri; Chi Wai Eric So
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

4.  Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.

Authors:  Molly C Kingsley; Hongbo M Xie; Bo-Rui Chen; Simone S Riedel; Taylor Pastuer; Madelyn K Bollig; Tyler Shank; Clara Libbrecht; Sally P Stabler; Aniruddha J Deshpande; Andrew M Intlekofer; Kathrin M Bernt
Journal:  Blood Adv       Date:  2020-07-14

Review 5.  Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia.

Authors:  Andrei V Krivtsov; Takayuki Hoshii; Scott A Armstrong
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

6.  Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.

Authors:  Michael W M Kühn; Evelyn Song; Zhaohui Feng; Amit Sinha; Chun-Wei Chen; Aniruddha J Deshpande; Monica Cusan; Noushin Farnoud; Annalisa Mupo; Carolyn Grove; Richard Koche; James E Bradner; Elisa de Stanchina; George S Vassiliou; Takayuki Hoshii; Scott A Armstrong
Journal:  Cancer Discov       Date:  2016-08-17       Impact factor: 39.397

7.  Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome.

Authors:  Sarah M Choi; Rajan Dewar; Patrick W Burke; Lina Shao
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

Review 8.  Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.

Authors:  Chun-Wei Chen; Scott A Armstrong
Journal:  Exp Hematol       Date:  2015-06-25       Impact factor: 3.084

9.  The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Authors:  Eytan M Stein; Guillermo Garcia-Manero; David A Rizzieri; Raoul Tibes; Jesus G Berdeja; Michael R Savona; Mojca Jongen-Lavrenic; Jessica K Altman; Blythe Thomson; Stephen J Blakemore; Scott R Daigle; Nigel J Waters; A Benjamin Suttle; Alicia Clawson; Roy Pollock; Andrei Krivtsov; Scott A Armstrong; Jorge DiMartino; Eric Hedrick; Bob Löwenberg; Martin S Tallman
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

10.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.

Authors:  Vincent-Philippe Lavallée; Irène Baccelli; Jana Krosl; Brian Wilhelm; Frédéric Barabé; Patrick Gendron; Geneviève Boucher; Sébastien Lemieux; Anne Marinier; Sylvain Meloche; Josée Hébert; Guy Sauvageau
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.